Piper Jaffray lowered its price target on Biogen (NASDAQ: BIIB) to $353.00 (from $407.00) while maintaining a Overweight rating.Analyst Chris ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

Biogen (BIIB) PT Lowered to $272 at Cantor FitzgeraldApril 26, 2018 1:49 AM Biogen (BIIB) PT Lowered to $311 at RBC CapitalApril 25, 2018 7:43 AM Biogen (BIIB) PT Raised to $369 at Morgan StanleyApril 25, 2018 7:24 AM Biogen (BIIB) PT Lowered to $375 at OppenheimerApril 25, 2018 7:15 AM Biogen (BIIB) PT Lowered to $325 at Leerink PartnersApril 25, 2018 6:37 AM Biogen (BIIB) PT Lowered to $385 at GuggenheimApril 25, 2018 2:03 AM